Choon Ok Kim

Prof. Choon Ok Kim

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SCSung Kweon Cho
Sung Kweon Cho
CKChoon Ok Kim
Choon Ok Kim
EPEun Seok Park
Eun Seok Park
JCJae-Yong Chung
Jae-Yong Chung

25 December 2024 in Journal of Advanced Research
Verified
Journal Article
Open access
WLWon-Yung Lee
Won-Yung Lee
KPKwang Il Park
Kwang Il Park
SBSeon-Been Bak
Seon-Been Bak
SLSeung-Ho Lee
Seung-Ho Lee
SBSu-jin Bae
Su-jin Bae
Chang-Eop KimChang-Eop Kim
Chang-Eop Kim
Network pharmacology has gained significant traction as a tool for identifying the mechanisms and therapeutic effects of herbal medicines. However, despite the usefulness of these approaches, their diversity underscores the critical need for a systematic evaluation to ensure consistency and reliability. We aimed to evaluate the network pharmacological analyses, focusing on identifying the mechanisms and therapeutic effects of herbal medicines. We employed a comprehensive approach involving systematic data retrieval, network construction, and analysis. Herbal compounds and their targets were meticulously extracted from five distinct network pharmacology databases to ensure extensive coverage and high data reliability. Advanced network-based methods were used to identify key herbal targets and predict therapeutic effects, thereby enriching the depth and breadth of the analysis. Experimental validation was performed on prostate cancer models to substantiate the computational predictions. The results of the recapitulating task for known herbal ingredient targets revealed distinct patterns in performance and coverage based on network construction and aggregation methods. We performed the same analysis to identify herbal targets and found that network centrality, path counts, and downweighted path counts had their own pros and cons. By comparing network-based methods, we found that considering the impact on the multiscale interactome yielded the highest accuracy in discriminating known therapeutic effects. Using optimal conditions, we successfully identified new indications for herbal medicines and validated these findings through follow-up in vitro and in vivo experiments. This study presents the first comprehensive and critical evaluation of the current network pharmacology analyses in the field of herbal medicine and provides valuable guidance for continued advances in the elucidation of the mechanisms and therapeutic effects.

8 December 2011 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
CKChoon Ok Kim
Choon Ok Kim
CNChung Mo Nam
Chung Mo Nam
DLDuk-Chul Lee
Duk-Chul Lee
JCJoon Chang
Joon Chang
JLJI WON LEE
JI WON LEE
Please cite this paper as: Kim et al. (2012) Is abdominal obesity associated with the 2009 influenza A (H1N1) pandemic in Korean school‐aged children? Influenza and Other Respiratory Viruses 6(5), 313–317.Objective  Given their medical vulnerabilities, we investigated the epidemiological factors related to H1N1 infection in school‐aged children.Methods  This study analyzed data collected on 7448 school‐aged children in South Korea between 18 November and 8 December 2009.Results  We found that H1N1 infection was associated with body mass index (BMI), waist circumference (WC), the use of facemasks, contact history with H1N1‐infected persons, and overseas travel history (P < 0·05). In addition, WC quartiles were significantly associated with H1N1 infection after adjusting for BMI and other confounding variables [OR (95% CI): 1·00, 1·10 (0·72–1·45), 1·13 (0·76–1·67), and 2·71 (1·74–4·24), respectively).Conclusions  Abdominal obesity and the use of facemasks appear to be independently associated with H1N1 infection in school‐aged children. We infer that providing education on wearing facemasks and specific planning for abdominally obese children and adolescents may be effective means of reducing the spread of the influenza pandemic in school‐aged children.

1 January 2013 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
EOEun Sil Oh
Eun Sil Oh
CKChoon Ok Kim
Choon Ok Kim
SCSung Kweon Cho
Sung Kweon Cho
MPMin Soo Park
Min Soo Park
JCJae-Yong Chung
Jae-Yong Chung
Pitavastatin, a 3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitor is distributed to the liver, a target organ of action and excreted mainly into the bile. To investigate the impact of influx (OATP1B1) and efflux (MRP2, BCRP) transporter alleles on its disposition, the pharmacokinetic (PK) parameters were compared among the following groups: SLCO1B1 (*15 carrier and non-carrier), ABCC2 (G1249A, C3972T, C-24T, G1549A, and G1774T), and ABCG2 (C421A) single nucleotide polymorphisms in 45 healthy Korean volunteers. Pitavastatin AUC(last) was higher in individuals carrying the SLCO1B1*15 allele than those not carrying it (144.1 ± 55.3 vs. 84.7 ± 25.7 h·ng/mL [mean ± SD], p = 0.002). The AUC(last) varied significantly according to the ABCC2 C-24T allele (103.4 ± 42.2, 80.2 ± 23.8, and 39.0 h·ng/mL in CC, CT and TT, respectively; p = 0.027). Other SNPs of ABCC2 and ABCG2 were not significant. The effect of these transporters and body weight on the AUC(last) and C(max) were tested, and only SLCO1B1 and ABCC2 C-24T genotypes were significant factors by analysis of covariance. These variants accounted for almost 50% of the variation in AUC(last) and C(max) of pitavastatin. Therefore, ABCC2 C-24T was significantly associated with pitavastatin human PK when the known effect of SLCO1B1*15 was also considered.

1 July 2013 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
JCJae-Yong Chung
Jae-Yong Chung
SCSung Kweon Cho
Sung Kweon Cho
TKTae Hee Kim
Tae Hee Kim
KKKyoung Hee Kim
Kyoung Hee Kim
GJGeun Hye Jang
Geun Hye Jang
JCJi Ha Choi
Ji Ha Choi
Human multidrug and toxin extrusion member 2 (MATE2-K, SLC47A2) plays an important role in the renal elimination of various clinical drugs including the antidiabetic drug metformin. The goal of this study was to characterize genetic variants of MATE2-K and determine their association with the pharmacokinetics of metformin. We screened DNA samples from 48 healthy Koreans for variants in the promoter and coding regions of MATE2-K and examined the function of common haplotypes in the promoter region using in-vitro luciferase assays. Then, the metformin pharmacokinetic study was carried out to determine the association between MATE2-K promoter haplotypes and metformin pharmacokinetics. Nine variants in the promoter region of MATE2-K and one nonsynonymous variant, p.G211V, were identified. The MATE2-K promoter haplotype 1 containing a known functional polymorphism, g.-130G>A and haplotype 2 containing two polymorphisms, g.-609G>A and g.-396G>A showed a significant increase in reporter activity. Among the 45 individuals who participated in the metformin pharmacokinetic study, 12 healthy Koreans who were homozygous for haplotype 1 or 2 showed a significant increase in renal clearance [539 ± 76 (reference group) vs. 633 ± 102 (variant group) ml/min; P=0.006] and secretion clearance [439 ± 81 (reference group) vs. 531 ± 102 (variant group) ml/min; P=0.007] of metformin compared with that shown by the reference group. Our study suggests that common promoter haplotypes of MATE2-K are associated with the pharmacokinetics of metformin.

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
HLHye Jun Lee
Hye Jun Lee
CKChoon Ok Kim
Choon Ok Kim
DLDuk-Chul Lee
Duk-Chul Lee
Lee HJ, et al. Yonsei Med J. 2021 Jul;62(7):593-599. https://doi.org/10.3349/ymj.2021.62.7.593